An effective pricing strategy requires long term planning
The Phase III trials need to be designed with the payer customer in mind

Which of the other HTA models is having the greatest influence in Europe?
What changes can we expect from the French and UK HTAs?

What can we learn from the first 15 months of the AMNOG reforms in Germany?
What implications do the reforms have for Germany and other European countries?

Despite the increasing importance of Health Technology Assessments most of Europe reference other countries to set their prices
Cross county referencing and parallel trade can be modelled to set floor prices and planned launch sequences

Using an analytical framework to ensure we plan our pricing strategies appropriately

How to put our learnings into practice